{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:10:19Z","timestamp":1794258619243,"version":"4.9.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T00:00:00Z","timestamp":1727568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011892","name":"Kaohsiung Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jmii.2024.09.006","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:12:11Z","timestamp":1727827931000},"page":"62-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"title":["Alternations of the gut microbiota and the Firmicutes\/Bacteroidetes ratio after biologic treatment in inflammatory bowel disease"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8593-6841","authenticated-orcid":false,"given":"Yu-Chieh","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chen","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6614-5937","authenticated-orcid":false,"given":"Chih-Ming","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Kun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chao","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Hsiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pao-Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0185-1846","authenticated-orcid":false,"given":"Yuan-Hung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4868-200X","authenticated-orcid":false,"given":"Chih-Chien","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8934-3223","authenticated-orcid":false,"given":"Seng-Kee","family":"Chuah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2024.09.006_bib1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jmii.2024.09.006_bib2","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jmii.2024.09.006_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7247238","article-title":"A comprehensive review and update on the pathogenesis of inflammatory bowel disease","volume":"2019","author":"Guan","year":"2019","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jmii.2024.09.006_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.999001","article-title":"Human gut microbiota in health and disease: unveiling the relationship","volume":"13","author":"Afzaal","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jmii.2024.09.006_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12328-017-0813-5","article-title":"Gut microbiota in the pathogenesis of inflammatory bowel disease","volume":"11","author":"Nishida","year":"2018","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.jmii.2024.09.006_bib6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","article-title":"Understanding and preventing the global increase of inflammatory bowel disease","volume":"152","author":"Kaplan","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jmii.2024.09.006_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/apt.12365","article-title":"Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis","volume":"38","author":"Varela","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"10114","key":"10.1016\/j.jmii.2024.09.006_bib8","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.jmii.2024.09.006_bib9","article-title":"Real-world effectiveness of vedolizumab vs anti-TNF in biologic-na\u00efve Crohn's disease patients: a 2-year propensity-score-adjusted analysis from the VEDOIBD-study","volume":"31","author":"Bokemeyer","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jmii.2024.09.006_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0016-5085(99)70224-6","article-title":"Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis","volume":"116","author":"Baert","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jmii.2024.09.006_bib11","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.3390\/ijerph17145120","article-title":"Evaluation of changes in gut microbiota in patients with Crohn's disease after anti-tnf\u03b1 treatment: prospective multicenter observational study","volume":"17","author":"Sanchis-Artero","year":"2020","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.jmii.2024.09.006_bib12","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2024.09.006_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.jmii.2024.09.006_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nmeth.f.303","article-title":"QIIME allows analysis of high-throughput community sequencing data","volume":"7","author":"Caporaso","year":"2010","journal-title":"Nat Methods"},{"key":"10.1016\/j.jmii.2024.09.006_bib15","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/gb-2011-12-6-r60","article-title":"Metagenomic biomarker discovery and explanation","volume":"12","author":"Segata","year":"2011","journal-title":"Genome Biol"},{"key":"10.1016\/j.jmii.2024.09.006_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.oraloncology.2017.12.005","article-title":"Compositional and functional variations of oral microbiota associated with the mutational changes in oral cancer","volume":"77","author":"Yang","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jmii.2024.09.006_bib17","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nbt.2676","article-title":"Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences","volume":"31","author":"Langille","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jmii.2024.09.006_bib18","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.3389\/fmicb.2018.02247","article-title":"The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease","volume":"9","author":"Zuo","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jmii.2024.09.006_bib19","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1053\/j.gastro.2014.02.009","article-title":"The microbiome in inflammatory bowel disease: current status and the future ahead","volume":"146","author":"Kostic","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jmii.2024.09.006_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3945\/ajcn.110.010132","article-title":"Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans","volume":"94","author":"Jumpertz","year":"2011","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jmii.2024.09.006_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-88823-2","article-title":"Evaluation of changes in intestinal microbiota in Crohn's disease patients after anti-TNF alpha treatment","volume":"11","author":"Sanchis-Artero","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmii.2024.09.006_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/msystems.00188-17","article-title":"Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction","volume":"3","author":"Zhou","year":"2018","journal-title":"mSystems"},{"key":"10.1016\/j.jmii.2024.09.006_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02120-17","article-title":"Fecal microbiota signatures are associated with response to ustekinumab therapy among Crohn's disease patients","volume":"9","author":"Doherty","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.jmii.2024.09.006_bib24","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.advms.2020.06.003","article-title":"Quantitative changes in selected bacteria in the stool during the treatment of Crohn's disease","volume":"65","author":"Salamon","year":"2020","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.jmii.2024.09.006_bib25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/ibd\/izac194","article-title":"Searching for a consensus among inflammatory bowel disease studies: a systematic meta-analysis","volume":"29","author":"Abdel-Rahman","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jmii.2024.09.006_bib26","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijmm.2014.02.009","article-title":"Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish irritable bowel syndrome and inflammatory bowel disease phenotypes","volume":"304","author":"Lopez-Siles","year":"2014","journal-title":"Int J Med Microbiol IJMM"},{"key":"10.1016\/j.jmii.2024.09.006_bib27","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/gutjnl-2015-310746","article-title":"Fungal microbiota dysbiosis in IBD","volume":"66","author":"Sokol","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jmii.2024.09.006_bib28","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ecco-jcc\/jjaa252","article-title":"Bacterial and fungal profiles as markers of infliximab drug response in inflammatory bowel disease","volume":"15","author":"Ventin-Holmberg","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jmii.2024.09.006_bib29","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1093\/ibd\/izaa253","article-title":"Fecal microbiota alterations associated with clinical and endoscopic response to infliximab therapy in Crohn's disease","volume":"26","author":"Zhuang","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jmii.2024.09.006_bib30","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1099\/ijs.0.064626-0","volume":"64","author":"De Maesschalck","year":"2014","journal-title":"Int J Syst Evol Microbiol"},{"key":"10.1016\/j.jmii.2024.09.006_bib31","article-title":"Gut microbiome and metabonomic profile predict early remission to anti-integrin therapy in patients with moderate to severe ulcerative colitis","volume":"11","author":"Liu","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jmii.2024.09.006_bib32","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3390\/microorganisms8030438","article-title":"The interplay between mucosal microbiota composition and host gene-expression is linked with infliximab response in inflammatory bowel diseases","volume":"8","author":"Dovrolis","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.jmii.2024.09.006_bib33","first-page":"1","article-title":"From correlation to causality: the case of Subdoligranulum","volume":"12","author":"Van Hul","year":"2020","journal-title":"Gut Microb"},{"key":"10.1016\/j.jmii.2024.09.006_bib34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1128\/CMR.00053-08","article-title":"Enterotoxigenic Bacteroides fragilis: a rogue among symbiotes","volume":"22","author":"Sears","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jmii.2024.09.006_bib35","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3390\/microorganisms9081686","article-title":"Association between gut microbiota and development of gestational diabetes mellitus","volume":"9","author":"Sililas","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.jmii.2024.09.006_bib36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13099-021-00446-0","article-title":"Gut microbiota influence in type 2 diabetes mellitus (T2DM)","volume":"13","author":"Cunningham","year":"2021","journal-title":"Gut Pathog"},{"key":"10.1016\/j.jmii.2024.09.006_bib37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/pathogens12020262","article-title":"Assessing the relationship between the gut microbiota and inflammatory bowel disease therapeutics: a systematic review","volume":"12","author":"Mah","year":"2023","journal-title":"Pathog Basel Switz."},{"key":"10.1016\/j.jmii.2024.09.006_bib38","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.3390\/microorganisms8111715","article-title":"The influence of probiotics on the firmicutes\/bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease","volume":"8","author":"Stojanov","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.jmii.2024.09.006_bib39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/biom12010056","article-title":"Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives","volume":"12","author":"Vallianou","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.jmii.2024.09.006_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49833-3","article-title":"Increased abundance of proteobacteria in aggressive Crohn's disease seven years after diagnosis","volume":"9","author":"Vester-Andersen","year":"2019","journal-title":"Sci Rep"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118224001841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118224001841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T02:44:39Z","timestamp":1740624279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118224001841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1684118224001841"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2024.09.006","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alternations of the gut microbiota and the Firmicutes\/Bacteroidetes ratio after biologic treatment in inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2024.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}